Acalabrutinib, Free Base

Acalabrutinib, Free Base
Item number Size Datasheet Manual SDS Delivery time Quantity Price
LC-A-7337_5mg 5 mg -

3 - 15 business days*

72.00€
LC-A-7337_10mg 10 mg -

3 - 15 business days*

86.00€
LC-A-7337_25mg 25 mg -

3 - 15 business days*

104.00€
LC-A-7337_50mg 50 mg -

3 - 15 business days*

128.00€
LC-A-7337_100mg 100 mg -

3 - 15 business days*

152.00€
LC-A-7337_200mg 200 mg -

3 - 15 business days*

236.00€
LC-A-7337_500mg 500 mg -

3 - 15 business days*

385.00€
LC-A-7337_1g 1 g -

3 - 15 business days*

626.00€
LC-A-7337_2g 2 g -

3 - 15 business days*

962.00€
 
Soluble in DMSO. Acalabrutinib, also known as ACP-196, is an irreversible Bruton tyrosine kinase... more
Product information "Acalabrutinib, Free Base"
Soluble in DMSO. Acalabrutinib, also known as ACP-196, is an irreversible Bruton tyrosine kinase (BTK) inhibitor. It binds covalently to Cys481 with improved selectivity and in vivo target coverage. Acalabrutinib inhibited BTK with an IC50 of 3 nM and had improved target specificity over ibrutinib with 323-, 94-, 19-, and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR. Wu J., et al. 'Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.' J. Hematol. Oncol. 9: 21 (2016). Acalabrutinib avoided major platelet dysfunction in non-Hodgkin lymphoma (NHL) patients associated with ibrutinib treatment. Bye A.P., et al. 'Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 1: 2610-2623 (2017). In an uncontrolled, phase 1-2, multicenter study, the selective and irreversible BTK inhibitor acalabrutinib demonstrated promising safety and efficacy profiles in patients with relapsed chronic lymphocytic leukemia (CLL), including those with chromosome 17p13.1 deletion. Byrd J.C., et al. 'Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.' N. Engl. J. Med. 374: 323-332 (2016).
Keywords: ACP196, ACP-196
Supplier: LC Laboratories
Supplier-Nr: A-7337

Properties

Application: Antineoplastic, Bruton's tyrosine kinase (BTK) inhibitor
MW: 465.51 D
Formula: C26H23N7O2
Purity: >99%
Format: Solid

Database Information

CAS : 1420477-60-6| Find alternatives
KEGG ID : K07370 | Find alternatives

Handling & Safety

Storage: -20°C
Shipping: +20°C (International: +20°C)
Signal Word: Warning
GHS Hazard Pictograms:
H Phrases: H302, H410
P Phrases: P264, P270, P273, P301+P312, P330, P391, P501
Caution
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow. more
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Acalabrutinib, Free Base"
Write a review
or to review a product.
Viewed